CY1112655T1 - Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις - Google Patents

Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις

Info

Publication number
CY1112655T1
CY1112655T1 CY20121100161T CY121100161T CY1112655T1 CY 1112655 T1 CY1112655 T1 CY 1112655T1 CY 20121100161 T CY20121100161 T CY 20121100161T CY 121100161 T CY121100161 T CY 121100161T CY 1112655 T1 CY1112655 T1 CY 1112655T1
Authority
CY
Cyprus
Prior art keywords
polypeptides
well
relates
preparation
cells
Prior art date
Application number
CY20121100161T
Other languages
English (en)
Inventor
Michel Morre
Brigitte Assouline
Iann Rance
Anne Gregoire
Corinne Breque
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytheris filed Critical Cytheris
Publication of CY1112655T1 publication Critical patent/CY1112655T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέα και βελτιωμένα πολυπεπτίδια ιντερλευκίνης-7, καθώς επίσης συνθέσεις που περιλαμβάνουν αυτά, παρασκευή αυτών και χρήσεις αυτών. Η εφεύρεση ειδικότερα αφορά σε υπεργλυκοζυλιωμένα ΙL-7 πολυπεπτίδια που έχουν βελτιωμένες ιδιότητες, καθώς επίσης τη βιομηχανική κατασκευή αυτών και θεραπευτικές χρήσεις αυτών. Η εφεύρεση επίσης αποκαλύπτει νέα πολυπεπτίδια IL-7 που έχουν τροποποιημένες αλληλουχίες αμινοξέος που περιέχουν τεχνητώς δημιουργούμενη θέση(-εις) γλυκοζυλίωσης, καθώς επίσης αντίστοιχα μόρια νουκλεϊνικού οξέος, φορείς και ανασυνδυασμένα κύτταρα ξενιστές. Η εφεύρεση επίσης αφορά στη χρήση τέτοιων πολυπεπτιδίων, κυττάρων ή νουκλεϊνικών οξέων για θεραπευτική ή προληπτική θεραπεία υποκειμένων θηλαστικών, συμπεριλαμβανομένων ανθρώπινων υποκειμένων.
CY20121100161T 2005-07-20 2012-02-16 Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις CY1112655T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291556A EP1746161A1 (en) 2005-07-20 2005-07-20 Glycosylated IL-7, preparation and uses
EP06795556A EP1904635B1 (en) 2005-07-20 2006-07-19 Glycosylated il-7, preparation and uses

Publications (1)

Publication Number Publication Date
CY1112655T1 true CY1112655T1 (el) 2016-02-10

Family

ID=35385570

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100161T CY1112655T1 (el) 2005-07-20 2012-02-16 Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις

Country Status (20)

Country Link
US (3) US7708985B2 (el)
EP (2) EP1746161A1 (el)
JP (2) JP5685363B2 (el)
CN (2) CN101228275B (el)
AT (1) ATE542901T1 (el)
AU (1) AU2006271315B2 (el)
CA (2) CA2859145C (el)
CY (1) CY1112655T1 (el)
DK (1) DK1904635T3 (el)
EA (1) EA012802B1 (el)
ES (1) ES2379732T3 (el)
HK (1) HK1115154A1 (el)
IL (1) IL188480A0 (el)
NO (1) NO344802B1 (el)
NZ (1) NZ564907A (el)
PL (1) PL1904635T3 (el)
PT (1) PT1904635E (el)
SI (1) SI1904635T1 (el)
WO (1) WO2007010401A2 (el)
ZA (1) ZA200800533B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
EP2066336B1 (en) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Use of pegylated il-10 to treat cancer
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
CN101943688B (zh) * 2009-07-10 2013-01-02 复旦大学 一种利用质谱靶板富集糖基化肽段的方法
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
NZ605640A (en) * 2010-07-19 2016-01-29 Otago Innovation Ltd Signal biomarkers
SG10201407036YA (en) 2010-11-05 2014-12-30 Transbio Ltd Markers of Endothelial Progenitor Cells and Uses Thereof
CA2820956C (en) * 2010-12-10 2016-05-03 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
KR20140063657A (ko) 2011-08-03 2014-05-27 사이세리스 Ｈｃｖ 면역요법
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN104725484B (zh) * 2013-12-19 2018-03-13 中国科学院微生物研究所 一种糖基化多肽及其制备方法和其应用
US20180028593A1 (en) 2014-03-21 2018-02-01 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN104372021A (zh) * 2014-11-05 2015-02-25 太仓思源生物医药有限公司 人白细胞介素-2蛋白质的制备方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
KR101873201B1 (ko) 2015-06-11 2018-07-02 주식회사 제넥신 변형된 인터루킨-7 단백질 및 이의 용도
JP6959229B2 (ja) * 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
KR102604595B1 (ko) 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
KR20170066265A (ko) 2015-12-04 2017-06-14 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CA3082975A1 (en) 2018-01-25 2019-08-19 I-Mab Biopharma Us Limited Anti-pd-l1 antibody and il-7 fusions
KR20210093950A (ko) 2018-11-16 2021-07-28 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
KR102402276B1 (ko) * 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
CN114945409A (zh) 2020-01-13 2022-08-26 新免疫技术有限公司 用il-7蛋白和双特异性抗体的组合***的方法
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
WO2022093718A1 (en) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN113817043B (zh) * 2021-09-22 2023-07-25 清华大学 制备活性铁调节激素的方法
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024150158A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
EP1299535A2 (en) * 2000-06-30 2003-04-09 Maxygen Aps Peptide extended glycosylated polypeptides
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof

Also Published As

Publication number Publication date
ES2379732T3 (es) 2012-05-03
US8153114B2 (en) 2012-04-10
US7708985B2 (en) 2010-05-04
US20080206190A1 (en) 2008-08-28
EA200800368A1 (ru) 2008-06-30
CN105647939A (zh) 2016-06-08
CN101228275A (zh) 2008-07-23
JP2009501543A (ja) 2009-01-22
AU2006271315B2 (en) 2011-08-11
AU2006271315A1 (en) 2007-01-25
ATE542901T1 (de) 2012-02-15
PL1904635T3 (pl) 2012-07-31
HK1115154A1 (en) 2008-11-21
NO20080045L (no) 2008-04-21
SI1904635T1 (sl) 2012-10-30
CA2859145A1 (en) 2007-01-25
EA012802B1 (ru) 2009-12-30
EP1904635B1 (en) 2012-01-25
US20100196312A1 (en) 2010-08-05
EP1904635A2 (en) 2008-04-02
JP2015057392A (ja) 2015-03-26
ZA200800533B (en) 2008-12-31
NO344802B1 (no) 2020-05-04
PT1904635E (pt) 2012-03-06
CA2615562C (en) 2014-11-04
WO2007010401A3 (en) 2007-04-19
US20120016104A1 (en) 2012-01-19
WO2007010401A2 (en) 2007-01-25
US8034327B2 (en) 2011-10-11
CA2859145C (en) 2018-11-27
JP5685363B2 (ja) 2015-03-18
CA2615562A1 (en) 2007-01-25
CN101228275B (zh) 2016-02-24
DK1904635T3 (da) 2012-02-27
EP1746161A1 (en) 2007-01-24
NZ564907A (en) 2011-09-30
BRPI0613747A2 (pt) 2011-02-08
IL188480A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
MX2008001865A (es) Proteinas de fusion de albumina.
MX2009002816A (es) Proteinas de fusion de albumina.
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
ATE323766T1 (de) Glykosylierte leptinzusammensetzungen und zugehörige verfahren
IL212653A0 (en) Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
ATE501728T1 (de) Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
BR0308180A (pt) protéinas de superfìcie de leptospira
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon